13th Apr 2016 07:43
LONDON (Alliance News) - Development-stage pharmaceutical company Vernalis PLC on Wednesday said it has successfully completed the single-dose bioavailability study on its CCP-08 cough and cold treatment.
CCP-08 is the third extended-release product developed for Vernalis by Tris Pharma Inc for the US prescription cough-cold market.
The product will now move to a multiple-dose study, Vernalis said, and subject to the successful outcome of the studies, filing of a new drug application with the US Food & Drug Administration remains on track for 2016.
"We are delighted with the continued progress of CCP-08 and look forward to further news flow from this programme during 2016," said Ian Garland, Vernalis's chief executive.
Vernalis shares were up 1.5% to 51.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Vernalis PLC